



Proposed Acquisition of Alent plc Investor Presentation

July 13, 2015



Safe Harbor



Please note that this presentation is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In this presentation, we discuss events or results that have not yet occurred or been realized, commonly referred to as “forward-looking statements” within the meaning of the federal securities laws, including statements regarding the impact of the acquisitions by Platform Specialty Products Corporation (“Platform”) of Percival S.A., including its agrochemical business, Agriphar (“Agriphar”), the Chemtura AgroSolutions business of Chemtura Corporation (“Chemtura AgroSolutions” or “CAS”), Arysta LifeScience Limited. (“Arysta”), as well as the proposed acquisition by Platform of the Electronic Chemicals and Photomasks businesses (the “EC and PM businesses”) of OM Group, Inc. (the “OMG Acquisition”) and the proposed offer by Platform to acquire the entire issued and to be issued share capital of Alent (the “Alent Acquisition”) on the business and financial results of Platform, including sales, adjusted EBITDA, capital expenditures, cash flows, earnings per share, expected or estimated revenue, the outlook for Platform’s markets and the demand for its products, estimated sales, segment earnings, net interest expense, income tax provision, restructuring and other charges, cash flows from operations, consistent profitable growth, free cash flow, future revenues and gross operating and adjusted EBITDA margin improvement requirement and expansion, organic net sales growth, bank debt covenants, the success of new product introductions, growth in costs and expenses, the impact of commodities and currencies and Platform’s ability to manage its risk in these areas, Platform’s ability to raise new debt or equity and to consummate acquisitions, estimated synergies in Platform’s new combined agrochemical businesses, and relating to the OMG Acquisition or Alent Acquisition, and the impact in general of acquisitions, divestitures, restructurings, and other unusual items, including Platform’s ability to successfully integrate and obtain the anticipated results and synergies from its consummated and future acquisitions.

These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those projected as a result of certain factors. A discussion of factors that could cause results to vary is included in Platform’s registration statement filed with the Securities and Exchange Commission (the “SEC”) on June 17, 2015, as amended, and periodic and other reports filed by Platform with the SEC, including under the heading “Risk Factors” in Platform’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Platform undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation also contains non-GAAP financial measures that may not be directly comparable to other similarly titled measures used by other companies, including EBITDA and adjusted EBITDA. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of such company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. Pursuant to the requirements of Regulation G, Platform has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the Appendix of this presentation. These non-GAAP measures are provided because management of Platform uses these financial measures in monitoring and evaluating Platform’s ongoing financial results and trends. Management uses this non-GAAP information as an indicator of business performance, and evaluates overall management with respect to such indicators. These non-GAAP measures should be considered in addition to, but not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Historical financial information relating to Agriphar was obtained directly from Percival S.A., its privately-held former parent company. Although we believe it is reliable, this information has not been verified, internally or independently. Historical financial information relating to Chemtura AgroSolutions was derived from segment reporting in Chemtura Corporation’s periodic reports and earnings press releases. Financial information for Arysta was derived from Arysta’s registration statement on Form F-1 filed with the SEC on September 9, 2014, which was withdrawn since Platform’s acquisition of Arysta and should not be relied upon, and from Arysta’s management. Historical financial information related to the EC and PM businesses of OM Group, Inc. was derived from OM Group, Inc.’s management estimates. The EC and PM businesses’ method of calculating their Adjusted EBITDA differs from Platform’s method of calculating Adjusted EBITDA. Historical financial information for Alent was derived from Alent’s periodic reports and management estimates. Alent’s method of calculating its Adjusted EBITDA also differs from Platform’s method. In addition, Alent’s financial information is prepared in accordance with non-GAAP that may or may not be comparable to Platform’s financial statements. Consequently, there is no assurance that the financial results and information for Agriphar, Chemtura AgroSolutions, Arysta, the EC and PM businesses, or Alent contained in this presentation are accurate or complete, or representative in any way of Platform’s actual and future results as a consolidated company.

Important Information



No Offer or Solicitation

This presentation is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation, or the solicitation of an offer, to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the transaction or otherwise. The transaction will be implemented solely pursuant to the terms of a scheme document, which will contain the full terms and conditions of the transaction, including details of how to vote in respect of the transaction. Any vote or other action in respect of the transaction should be made only on the basis of the information in the scheme document.

Important Additional Information

The shares of common stock of Platform to be issued under the transaction (“New Platform Shares”) have not been and are not expected to be registered under the Securities Act of 1933, as amended (the “Act”) or under the securities laws of any state or other jurisdiction of the United States. It is expected that the New Platform Shares will be issued in reliance upon an exemption from the registration requirements of the Act, set forth in Section 3(a)(10) thereof. Shareholders of Alent (whether or not US persons) who are or will be affiliates (within the meaning of the Act) of Platform or Alent prior to, or of Platform after, the effective date will be subject to certain US transfer restrictions relating to the New Platform Shares received pursuant to the scheme of arrangement.

Platform reserves the right, subject to the prior consent of the U.K. Panel on Takeovers and Mergers and the terms of the Co-operation Agreement dated July 13, 2015, to elect to implement the transaction by way of a takeover offer (as such term is defined in the U.K. Companies Act 2006). Any securities to be issued in connection with such transaction may be issued in reliance on an exemption from the registration requirements of, or, alternatively, registered under the Act. If, in the future, Platform exercises its right to implement the transaction by way of a takeover offer in which New Platform Shares are to be issued in a manner that is not exempt from the registration requirements of the Act, Platform will file a registration statement with the SEC that will contain a prospectus with respect to the issuance of New Platform Shares. In this event, shareholders of Alent are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information, and such documents will be available free of charge at the SEC’s website at <http://www.sec.gov> or by contacting Platform’s Investor Relations department in writing at 1450 Centrepark Boulevard, Suite 210, West Palm Beach, Florida 33401.

None of the securities referred to in this presentation have been approved or disapproved by the SEC, any state securities commission in the United States or any other US regulatory authority, nor have such authorities passed upon or determined the adequacy or accuracy of the information contained in this presentation. Any representation to the contrary is a criminal offence in the United States.

No profit forecast or estimates

No statement contained herein (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement contained herein should be interpreted to mean that earnings per Platform’s share for the current or future financial years would necessarily match or exceed the historical published earnings per Platform’s share.

Transaction Summary



- Platform has announced a recommended offer to acquire the entire issued share capital of Alent

Offer value

- £5.03 per share
- Offer represents a total Alent enterprise value of US\$2,254 million⁽¹⁾

Structure

- 78% cash and 22% stock
- Full cash offer with partial share alternative for up to 22% of Alent shares
- Partial share alternative exchange ratio of 0.31523 Platform shares⁽²⁾
- Hard irrevocable undertaking from Cevian (22% shareholder in Alent) to elect for the share alternative in respect of their entire holding in Alent

Timing

- Expected to close at the end of 2015 or early 2016

Expected synergies⁽³⁾

- \$50 million of annual pre-tax cost synergies

1. Based on GBP / USD FX rate of 1.5517 at Platform market close on 7/10/2015.

2. Based on Platform share price of US\$24.76, being the VWAP on 7/10/2015 and a GBP / USD FX rate of 1.5517.

3. These estimated synergies have been made in accordance with, and reported on under, the UK Takeover Code by PricewaterhouseCoopers LLP and Credit Suisse. Further details of the synergies and copies of their letters are included in the announcement published by Platform on today's date that can be found at www.platformspecialtyproducts.com.

Alent Acquisition: Strategic Rationale

- Highly complementary businesses
 - Augments legacy MacDermid capabilities, technology and geography
 - Adds attractive new assembly materials business to Performance Applications product segments
 - Exemplary “Asset-Lite, High-Touch” business model
 - Similar ‘bookends’ strategy with emphasis on innovation and technical service
 - Enhanced geographic footprint
 - Significant synergy potential through integration
-

Alent Business Overview

Segment	Key Products	End-market
Assembly Materials (ALPHA)	Electronic interconnect materials <ul style="list-style-type: none">Printed circuit board assemblySemiconductor packaging	Predominantly Electronics Industry Focused
Surface Chemistries (ENTHONE)	Specialty electroplating chemicals <ul style="list-style-type: none">Semiconductor fabricationPrinted circuit board fabricationCorrosion, wear-resistant, and decorative coatings	Serving Mainly the Electronics and Automotive/Industrial Industries


Bringing Metals & Chemistry Together

A global supplier of specialty chemicals and engineered materials

Alent Financial Overview


Revenue (NSV)⁽¹⁾

(\$ in millions)




Adjusted EBITDA

(\$ in millions)




EBITDA – CapEx

(\$ in millions)



CapEx

(\$ in millions)



Note: For a reconciliation of Non-GAAP financials, please refer to the appendices of this presentation.

Alent financials converted from GBP to USD at average exchange rate over the year. 2011: 1.60; 2012: 1.59; 2013: 1.56; 2014: 1.65.

- Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
- Alent 2012 CapEx excludes \$9 million relating to the purchase of land and buildings.

Alent Fits our Strategic Acquisition Criteria



Platform's Investment Criteria




- “Asset-Lite, High-Touch” business model
- High cash flow margins and strong customer relationships
- Well-established across specialized product areas
- Diversified revenue base
- Accretive to intrinsic value per share



Alent Enhances the Performance Applications Segment


2014 Revenue⁽¹⁾

(\$ in millions)




2014 EBITDA


(\$ in millions)



PF Sales (By Geography)⁽¹⁾



PF Sales (By End Market)




Note: For a reconciliation of Non-GAAP financials, please refer to the appendices of this presentation.
 PF Platform and Alent excludes OM Group's EC and PM businesses.
 Alent financials converted from GBP to USD at average exchange rate over the year. 2014: 1.65.
 Alent EBITDA includes \$12 million of corporate costs.

- Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
- Performance Applications represents consolidated Platform less the Agricultural Solutions Segment and includes corporate overhead costs for Platform in 2014.


Alent Balances the Platform Portfolio

2014 Revenue⁽¹⁾ by Business Segment

(\$ in millions)




2014 Revenue: \$2,993 million




2014 PF Revenue⁽¹⁾: \$3,673 million

2014 EBITDA by Business Segment

(\$ in millions)



2014 EBITDA: \$642 million



2014 PF EBITDA: \$814 million


Note: For a reconciliation of Non-GAAP financials, please refer to the appendices of this presentation.
PF Platform and Alent includes Agricultural Solutions segment but excludes OM Group's EC and PM businesses.
Alent financials converted from GBP to USD at average exchange rate over the year. 2014: 1.65.

1. Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
2. Performance Applications includes legacy Platform Performance Materials and Alent's Surface Chemistries and Assembly Materials.

Pro Forma Platform Financial Profile


PF Revenue⁽¹⁾

(\$ in millions)




PF Adjusted EBITDA and Margin

(\$ in millions)




PF CapEx

(\$ in millions)



EBITDA – CapEx

(\$ in millions)




Source: For a reconciliation of Non-GAAP financials, please refer to the appendices of this presentation.

Note: Alent financials converted from GBP to USD at average exchange rate over the year. 2011: 1.60; 2012: 1.59; 2013: 1.56; 2014: 1.65.

- Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by the Divisions.
- Alent 2012 CapEx excludes \$9 million relating to the purchase of land and buildings.

Significant Synergy Potential

- \$50 million⁽¹⁾ of estimated synergies from Alent combination
- \$20 million* of additional expected synergies from OMG EC and PM businesses
- \$5 million* of Agricultural Solutions synergies realized in same quarter as Arysta close




Source: Management estimates.

Note: Figures marked with an * are not quantified benefits statement for the purposes of the UK Takeover Code because they do not depend upon the success of the offer for Alent.


- These estimated synergies have been made in accordance with, and reported on under, the UK Takeover Code by PricewaterhouseCoopers LLP and Credit Suisse. Further details of the synergies and copies of their letters are included in the announcement published by Platform on today's date that can be found at www.platformspecialtyproducts.com.

Platform Acquisition Timeline



Alent Strengthens Core Businesses, Diversifies Portfolio and Enhances Capabilities

Platform is executing a global build-up of high quality, high cash flow specialty chemical businesses across a diverse range of verticals



Source: Assembly Materials market opportunity from Prismark and Alent management analysis. Other market opportunities from Platform management.

Note: Assembly Materials market opportunity converted from GBP to USD at 1.55 exchange rate as of 7/10/2015.



Performance Applications



EC and PM
Businesses




Agricultural Solutions



Arysta LifeScience

Appendix



MacDermid Reconciliation of Net Income to Adjusted EBITDA Predecessor/Successor Combined



(\$ in millions)	December 31,		
	2012	2013	2014
Net income (loss) available to common stockholders	\$46	(\$180)	(\$7)
Adjustments to reconcile to net income (loss):			
Interest expense	\$50	\$52	\$36
Income tax expense	25	7	(3)
Depreciation and amortization expense	42	46	76 ⁽¹⁾
FX gain	(6)	(1)	–
Manufacturer's profit in inventory adjustment	–	24	12 ⁽²⁾
Non-cash fair value adjustment to contingent consideration	–	–	29 ⁽³⁾
Preferred dividend valuation	–	172	– ⁽⁴⁾
Acquisition costs	–	32	46 ⁽⁵⁾
Debt extinguishment	–	18	– ⁽⁶⁾
Impairments	–	–	–
Other expense, net	5	10	7
Adjusted EBITDA	\$162	\$180	\$196

(1) Includes \$31 million and \$57 million in 2013 and 2014, respectively, for amortization expense related to intangible assets recognized in purchase accounting for the MacDermid Acquisition.

(2) Adjustment to reverse manufacturer's profit in inventory purchase accounting adjustment associated with MacDermid Acquisition.

(3) Adjustment to fair value of contingent consideration in connection with the MacDermid Acquisition primarily associated with achieving the share price targets.

(4) Non-cash charge related to preferred stock dividend rights.

(5) Adjustment to reverse deal costs primarily in connection with the MacDermid Acquisition for 2013 and the Chemtura, Arysta and Agriphar Acquisitions for 2014. The Arysta Acquisition closed in 2015.

(6) Adjustment to reverse debt extinguishment charge in 2013 in connection with debt incurred as a result of a recapitalization.

Arysta Reconciliation of Net Income to Adjusted EBITDA



(\$ in millions)	December 31,		
	2012	2013	2014
Net (loss) available to common stockholders	(\$161)	(\$102)	(\$31)
Adjustments to reconcile to net income (loss):			
Interest expense	\$136	\$135	\$116
Income tax expense	45	48	50
Depreciation and amortization expense	74	67	68
Other credit agreement adjustments	34	36	35 ⁽¹⁾
FX loss	37	40	17
Impairments	–	49	35 ⁽²⁾
Derivatives losses	31	1	–
Discontinued operations	73	12	1 ⁽³⁾
Non-controlling interests	9	9	9
Other expense, net	(2)	(1)	(1)
Adjusted EBITDA	\$276	\$294	\$299

(1) Adjustments provided for in credit agreement to compute Adjusted EBITDA.

(2) Adjustment to reverse non-cash impairments of product registration rights of \$48 million and \$20 million and goodwill of \$0 and \$15 million during 2013 and 2014, respectively.

(3) Includes discontinued operations for the Midas business and FES group of companies.

Chemtura AgroSolutions

Reconciliation of Net Income to Adjusted EBITDA



(\$ in millions)	December 31,		
	2012	2013	2014
Net income available to common stockholders	\$39	\$47	\$28
Adjustments to reconcile to net income (loss):			
Interest expense	\$1	–	\$2
Income tax expense	18	29	40
Depreciation and amortization expense	15	14	19 ⁽¹⁾
FX loss (gain)	–	8	(4)
Manufacturer's profit in inventory adjustment	–	–	14 ⁽²⁾
Other expense, net	6	3	8
Adjusted EBITDA	\$79	\$101	\$107

(1) Includes \$7 million of amortization related to intangibles recognized in purchase accounting in 2014.

(2) Includes \$14 million of inventory step up recognized in purchase accounting in 2014.

Agriphar

Reconciliation of Net Income to Adjusted EBITDA



(\$ in millions)	December 31,		
	2012	2013	2014
Net income available to common stockholders	\$19	\$24	\$13
Adjustments to reconcile to net loss:			
Interest expense	\$2	\$2	\$1
Income tax expense	9	11	7
Depreciation and amortization expense	4	4	8 ⁽¹⁾
FX gain	–	–	(1)
Manufacturer's profit in inventory adjustment	–	–	9 ⁽²⁾
Other expense, net	1	–	7
Adjusted EBITDA	\$35	\$41	\$44

Note: 2012 Agriphar financials are unaudited.

(1) Includes \$3 million of amortization related to intangibles recognized in purchase accounting in 2014.

(2) Includes \$9 million of inventory step up recognized in purchase accounting in 2014.

Alert Reconciliation of Net Income to Adjusted EBITDA

(£ in millions)	December 31,		
	2012	2013	2014
Net income (loss) available to shareholders	£45	£62	£47
Adjustments to reconcile net income (loss):			
Pro forma adjustment to operating profit before JVs and exceptionals	(6)	–	–
Depreciation	9	9	9
Share of post-tax joint venture profit	(0)	(1)	(2)
Exceptional items ⁽¹⁾	16	10	18
Demerger costs	11	–	–
Net finance costs	4	7	5
Income tax costs	28	16	27
Adjusted EBITDA	£106	£103	£104

(1) Includes \$4 million, \$10 million and \$8 million in 2012, 2013 and 2014, respectively, for restructuring; includes \$7 million loss on construction contract in 2012; includes \$7 million of litigation and settlement charges in 2014; includes \$6 million and \$3 million of disposal and closure costs in 2012 and 2014, respectively; includes \$2 million of impairment charges in 2014; includes \$2 million of litigation settlement income in 2014; includes \$0.2 million of profit on disposal of operations in 2014.